A Study of A-CAR028 Treatment in Subjects With Relapsed/ Refractory Acute Myeloid Leukemia
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18 to 75 years old at the time of signing the Informed Consent Form (ICF)
• More than 12 weeks of expected survival
• ECOG score 0 or 1
• Relapsed or refractory AML
• Adequate organ function
Locations
Other Locations
China
Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITING
Hangzhou
Contact Information
Primary
Jie Jin, MD
jiej0503@163.com
+86-0571-87236898
Backup
Huafeng Wang, MD
1509036@zju.edu.cn
+86-0571-87236898
Time Frame
Start Date: 2025-09-30
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 20
Treatments
Experimental: A-CAR028
Autologous A-CAR028 administered by intravenous (IV) infusion
Related Therapeutic Areas
Sponsors
Collaborators: Shanghai AbelZeta Ltd.
Leads: First Affiliated Hospital of Zhejiang University